The collaboration with UBC is focused on developing machine-learning based technology to improve the quality of our 3D printing.
The presentation will highlight milestone achievements to develop human liver tissue using Aspect’s microfluidic 3D bioprinting platform.
McMaster University will use the RX1 3D Bioprinter to investigate novel disease mechanisms for chronic lung diseases.
This $2.2M project is made possible by contributions from CQDM, CCS, Merck, GSK, Aspect Biosystems, and McGill University.
Aspect collaborates with the Center for Minimally Invasive Therapies (C-MIT) at the University of California, Los Angeles (UCLA).
Aspect will join 15 ventures from around the world in a multi-year collaboration to help align the future of work with social equity.
Aspect Biosystems Named 2019 Growth Stage Company of the Year by LifeSciences BC.
The National Research Council of Canada and Aspect Biosystems are collaborating to develop a 3D model of the blood-brain barrier.
Aspect is presenting preclinical data from recent studies focused on developing a bioprinted meniscus tissue for surgical implantation.
The Maastricht Institute for Technology-Inspired Regenerative Medicine will develop kidney tissue using an RX1™ Bioprinting Platform.
Government of Canada invests nearly $20M in top British Columbia companies in 2018.
BIOTECanada Gold Leaf Award Winner for Emerging Company of the Year 2018: Aspect Biosystems.
Spiro joins Aspect following his role as Biology Director at GlaxoSmithKline and as a Faculty Member at Northwestern University.
Aspect Biosystems announces collaboration with multinational JSR Corporation to develop human liver tissue.
The Stem Cell Networks appoints Tamer Mohamed, CEO of Aspect Biosystems, to its Board of Directors
Genome BC Invests $1 million in Funding to Top Canadian 3D Bioprinting Company Aspect Biosystems.
BCBusiness includes Aspect CEO among the top young business leaders in BC
This Ready to Rocket list profiles the highest growth tech companies in BC's life science sector.
Aspect has announced the completion of its first institutionally led round of financing.
CEO Tamer Mohamed has been selected by Business in Vancouver for their annual Forty Under 40 Awards.
Aspect enters international research collaboration with InSCREENeX and Fraunhofer ITEM to develop bioprinted models of tissue contraction.
We're proud to be named one of the CIX (Canadian Innovation Exchange) Top 20 Most Innovative Canadian Technology Companies...
We're pleased to announce a research collaboration with University of Manitoba Professor Adrian West.
Aspect is pleased to announce that Dr. Peter Zandstra will join the company as an advisor.
We announced today that we have entered into a research collaboration with DePuy Synthes Products Inc.
We're pleased to announce that we've been selected to join the Canadian Technology Accelerator San Francisco (CTA SF) Life Sciences program.
We're pleased to announce that we have entered into a research collaboration with University of Victoria Professor Stephanie Willerth.
We have announced the appointment of James Hatton and Paul Drohan to our Board of Directors.
Aspect Biosystems Ltd. is pleased to announce that Mr. Dirk Smith will join the company as an advisor.
We're proud to be sponsoring the Biofabrication 2016 Conference and presenting our poster on 3D Bioprinting.
Today we announced the completion of an oversubscribed financing.
We're pleased to announce that we've been awarded $450,000 CAD in grant funding by the National Research Council.
We've been named winner of the ‘Most Promising Startup’ Award at the BC Tech Association’s 2016 Technology Impact Awards (TIAs).
Aspect Biosystems is pleased to announce the appointment of Tamer Mohamed as President and Chief Executive Officer effective May 3, 2016.
Aspect Biosystems was recognized by Startup Canada as a BC & the North Regional Winner of the Startup Canada Award for Innovation.
Aspect closes oversubscribed seed round funded by the local Vancouver angel community.
Aspect earns second place at the 2014 BCIC New Ventures Competition.
Aspect receives investment from e@UBC Seed Fund.
Aspect receives federal government support for validation of its first 3D printed tissue product